Aurealis Therapeutics

Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company that focuses on developing multi-target cell and gene therapies to address unmet medical needs in areas such as Chronic Wounds, deadly Cancers, and Inflammation. The company's platform is based on genetically modified safe lactic acid bacteria. Having completed a successful Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with their lead clinical product AUP-16, Aurealis Therapeutics is currently conducting a Phase 2 study in Italy, Germany, and Poland, with plans to extend to Venous Ulcers and other ulcers. In the field of Oncology, they are leveraging impressive pre-clinical data with their lead candidate AUP-55, showing increased survival in Ovarian Cancer and peritoneal carcinomatosis. Additionally, the company's pipeline includes Inflammation at the discovery stage. Founded in 2015 and headquartered in Finland, Aurealis Therapeutics received a $10.00M Series A investment on 30 March 2023 from investors Tesi, Lynx Capital, and Zhejiang Huahai Pharmaceutical. With its innovative approach and promising pipeline, Aurealis Therapeutics presents an intriguing opportunity for further growth and breakthroughs in the biotechnology and pharmaceutical industries.